Send us Fan Mail

What real-world use reveals about a medical device that no clinical trial ever could — and why the most dangerous moment in med tech innovation often comes after success, not before. A conversation about the fatigue failures, reimbursement gaps, and feedback breakdowns that surface only at scale.

For ten episodes, the From Idea to Market series has followed medical innovation through every threshold an idea must survive — the first clinical insight, the years of iteration, the funding rounds, the regulatory climb, the investor's decision room. Episode 10 asks what happens after all of that succeeds. When a product is working, when demand is building, when expectations have risen, what new vulnerabilities does that very success create?

Joe Schwab is joined by four voices who have lived this stage from different positions. Jared Foran is an orthopaedic surgeon in Denver and co-founder and chief scientific officer of Forcast Orthopedics. Doug Fairbanks is the president, CEO, and board member at VISIE Inc. Charlie DeCook is the president of Total Joint Specialists, a 17-surgeon group in Atlanta. Robert Cohen is the vice president of innovation and technology for Stryker's orthopaedic group, with four decades of watching the commercial environment for med tech innovation shift around him.

The episode works through three questions: what does real-world use reveal that no development program ever can, which structural and commercial weaknesses surface only at scale, and how do teams build the organizational discipline to act on what the market tells them. The conversation moves from product iteration after launch, to the second valley of death between regulatory clearance and reimbursement, to the feedback loops inside an organization that determine whether real-world signals reach the people who can act on them. For surgeon-founders, for engineers in med tech, and for anyone trying to understand why so many clinically promising ideas stall after they reach the market, this episode is about what scale actually demands.

⏱️ Chapters:
00:00 What happens to medical devices after they reach the market
02:53 Surgeons and industry leaders who scaled med tech innovations
04:35 The fatigue failure principle applied to medical devices
06:05 What real-world use reveals that clinical trials never can
09:15 Why most med tech products require a major pivot post-launch
11:33 How to sustain commercial momentum after launch
14:32 The second valley of death between clearance and reimbursement
16:13 Inside the new FDA-CMS RAPID coverage pathway
17:36 How reimbursement uncertainty kills good clinical ideas
22:35 Building feedback loops before scale exposes the gaps
25:39 Why launch is the start of development, not the end
30:55 Preview: built to last or built to sell

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#anteriorhipfoundation   #AHFPodcast #MedTech #MedTechInnovation #FromIdeaToMarket #PostMarketSurveillance #MedicalDevices #Reimbursement #FDA #ValleyOfDeath #Stryker #OrthopedicSurgery

Send us Fan Mail

Alex Sah on what it actually takes for a practicing surgeon to develop new orthopaedic tools — from first idea to OR adoption.

An honest conversation about mentors, mistakes, AI, and knowing when to walk away from a collaboration.

Most surgeons spot problems in the OR daily and quietly adapt to the limits of existing tools. Alex Sah, a high-volume hip and knee surgeon in Silicon Valley and Chief Medical Officer at Think Surgical, has chosen instead to engage directly with industry — first as an evaluator, then as an advisor, and eventually as a design partner. In this conversation with Joe Schwab, he walks through how that progression actually works in practice, and why he thinks every surgeon with a good idea owes it to themselves to start the process now rather than later.

The discussion gets practical fast. Alex breaks down how to vet an idea with a mentor and a patent search, why timing and portfolio fit can make or break a great concept, how to set milestones that let you walk away gracefully from a stalled collaboration, and why the technologies that succeed are usually the ones that speak for themselves the first time a surgeon uses them. He also shares a small habit with big implications — keeping his OR team blinded when testing new products to neutralize the placebo effect that quietly distorts informal evaluations.

The conversation closes on AI's inevitable arrival in orthopaedics, the surgeon's role in shaping it before it gets shaped for us, and the AHF Shark Tank as a live laboratory for the From Idea to Market journey. If you've been sitting on an idea, or wondering whether to take that next call from a device rep with a prototype, this episode is a realistic map of the road ahead.

⏱️ Chapters:
00:00 Introduction and Silicon Valley innovation roots
01:02 Why surgeons should solve problems instead of adapting
03:25 Surgeon roles in product development
04:24 First steps for surgeons with no industry connections
05:41 Turning a clinical idea into a development concept
06:46 Setting milestones and knowing when to walk away
08:01 Lessons from working with Think Surgical
10:50 Evaluating new surgical technology objectively
12:14 Essential advice for first-time surgeon innovators
15:47 Why surgeons must help shape AI in orthopaedics
17:40 Inside the AHF Shark Tank for surgical innovation

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #AlexanderSah #SurgeonInnovator #MedicalDeviceDevelopment #ThinkSurgical #Ospitek #OrthopaedicInnovation #JointReplacement #HipAndKneeSurgery #AIinSurgery #FromIdeaToMarket #MedTech #SurgicalRobotics

Send us Fan Mail

What med tech investors and strategic acquirers actually evaluate when a founder walks into the room — and what separates the pitches that earn capital from those that don't. A conversation drawn from people who've sat on both sides of the table.

For nine episodes, the From Idea to Market series has followed innovation from the founder's perspective — the problem noticed in a clinic, the iteration through years of prototypes, the regulatory climb, the manufacturing scale-up. Episode nine flips the lens. For the first time, the conversation moves into the room where decisions about that founder get made: by investors, by strategic acquirers, by the people whose capital and reputation come along with a yes.

Joe Schwab is joined by voices who've lived this evaluation from every side. Charles Lawrie is a co-founder and chief medical officer at FIOS Health and the current president of the Anterior Hip Foundation. Charlie DeCook is the president of Total Joint Specialists and has watched dozens of Shark Tank pitches at AHF annual meetings. Alex Sah is past AHF president, chief medical officer at Think! Surgical, and chief innovation officer at Ospitek. Robert Cohen, vice president of innovation and technology for Stryker's orthopaedic group, has spent four decades evaluating med tech ideas from inside startups and from inside one of the largest companies in the field.

The episode unpacks three questions: what truly drives the decisions made behind closed doors, how clinical value and financial logic and strategic interest actually intersect in real time, and which kinds of narrative survive due diligence — and which collapse the moment scrutiny begins. For surgeon-founders preparing to pitch, for clinicians thinking about their first innovation, and for anyone curious about how med tech capital actually gets allocated, this episode lays out what the decision room is really testing.

⏱️ Chapters:

00:00 Why this episode flips perspective from founder to investor

02:42 Surgeons and industry leaders inside the med tech decision room

04:46 What investors actually look for in a med tech pitch

08:23 How to structure a 15-minute med tech pitch

13:30 Where clinical value, profit, and strategy intersect

15:30 Why a great med tech idea can fail to scale

18:36 Why founders should pitch with a CEO at their side

22:02 How honest narrative wins under due diligence scrutiny

26:40 Stick to your competency: advice from a Stryker VP

29:12 What the decision room is really testing

31:43 Preview: when scaling success threatens to break the company

Listen to the AHF Podcast on your preferred platform:

Buzzsprout: https://ahfpodcast.buzzsprout.com

Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487

Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc

LinkedIn: https://www.linkedin.com/showcase/ahf-podcast

YouTube: https://www.youtube.com/@anteriorhipfoundation

Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #MedTech #MedTechInnovation #FromIdeaToMarket #MedicalDevices #MedTechInvesting #OrthopedicSurgery #StartupPitch #VentureCapital #Stryker #SharkTank

Send us Fan Mail

Charles Lawrie, MD — president of the Anterior Hip Foundation and a high-volume anterior approach hip and robotic knee surgeon in Miami — walks us through how a frustration in his own clinic became FIOS Health, an AI-powered patient communication platform now used in orthopaedic practices across the United States. This is an extended From Idea to Market conversation about the often lonely process of turning a clinical observation into a commercialized med-tech product, and what surgeons should know before they try.

Most surgeons see the same pattern every week: a flood of routine post-op questions about swelling, walking, showering, and driving that consumes clinic staff and amplifies patient anxiety. Lawrie's argument is that the bottleneck isn't surgical expertise — it's access to timely, trusted information, and that scaling that information is a fundamentally different problem than scaling clinical capacity.
We get into why he chose an AI-first product layered on familiar SMS and WhatsApp instead of yet another app, how he found a complementary co-founder in engineer and serial entrepreneur Andrew McDaid, what he had to unlearn to translate clinical expertise into product-market fit, and where FIOS Health is heading next — from answering patient questions to acting as an intelligence layer for the entire clinic.

If you're a surgeon thinking about innovation, this is a candid look at what it actually involves: starting with a problem you live every day, resisting the urge to build alone, defining a minimum viable product, and sitting with the daily self-doubt that comes with taking an idea to market.

https://fioshealth.com/

⏱️ Chapters:
00:00 Introducing Charles Lawrie and FIOS Health
01:14 Why patients struggle with information access after surgery
03:26 Solving staff scarcity and patient anxiety at the same time
05:43 Why AI plus SMS beats yet another patient app
08:53 Turning a clinical observation into a startup
13:07 The mahogany desk vision for patient care
18:21 Finding product market fit in a busy clinic
22:41 How FIOS becomes a surgeon's digital twin
26:50 Advice for surgeons who want to build a company
29:43 The intelligence layer for the entire clinic

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #FIOSHealth #CharlesLawrie #FromIdeaToMarket #MedTechStartup #OrthopaedicInnovation #AIinHealthcare #PatientEngagement #HipArthroplasty #SurgeonEntrepreneur #DigitalHealth #ClinicalWorkflow

Send us Fan Mail

What does it actually take to move a medical device from a working prototype to a product that can be built reliably at volume? In this episode of From Idea to Market, surgeons, founders, and attorneys describe the discipline that separates an approved device from a scalable company.

Most medical device teams underestimate what happens after a prototype works. Manufacturing at scale is a different problem from manufacturing at all, and the assumption that the hard work is done once the device is validated tends to be the most expensive miscalculation in med tech. This episode unpacks the transition from a hand-tuned engineering project to a controlled, reproducible production system, and why the process itself, not the device, becomes the real product.

Jared Foran of Forcast Orthopedics, Leo Whiteside, Marie-Isabelle Batthyány of XRSynergies, Charles Lawrie of FIOS Health, Charlie DeCook of Total Joint Specialists, attorney Emily Ast, and Simon Mifsud of Garland Surgical share what they have learned from inside this transition. The conversation covers ISO 13485, design for manufacturability, supplier qualification, the economics of hardware versus software, supply chain design as part of the device itself, the kinds of problems that only surface at volume, and the contract clauses that quietly determine whether a successful product remains a fair deal once it scales globally.

If you build, fund, regulate, or use medical devices, this episode is for you. It is the part of innovation that gets the least attention and decides the most outcomes — the daily, unglamorous work of building systems reliable enough that the product performs the same way every time, no matter who is in the room.

⏱️ Chapters:
00:00 Why scaling production breaks medical devices
02:57 Meet the founders, surgeons, and attorneys
05:30 What design freeze means in medical devices
06:46 Why the process becomes the product, not the device
09:32 Bringing manufacturing partners in before design freeze
12:18 The three-times rule of medical device development
15:59 Quality, cost, and scalability at production scale
18:02 Why hardware med tech is harder than software
20:18 Designing surgical kits for real-world supply chains
25:22 Problems that only emerge at production volume
28:11 Why founders should titrate the speed of scale
30:45 IP clauses and royalty timing for global products
34:58 What scale really proves about a medical device company

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #FromIdeaToMarket #MedTech #MedicalDeviceDevelopment #ISO13485 #DesignForManufacturability #DFM #QualityManagementSystem #MedTechScaling #OrthopedicInnovation #SurgicalInnovation #MedicalDeviceManufacturing #MedTechFounders

Send us Fan Mail

There is no such thing as an off-the-record innovation discussion. Even a casual conversation over drinks can create a factual record of idea sharing that impacts patent ownership, joint development leverage, and your negotiating position for years. Emily Ast, a contract attorney whose practice is 75 percent orthopedics, explains exactly what surgeon innovators need to know before they say a word to anyone — including friends and family.

Ast breaks down the two main contract types innovators encounter: general consulting agreements and intellectual property development agreements. She identifies the single clause she sees surgeons consistently underestimate — the product or project scope definition — and shows how a description that is even slightly too broad can transfer far more IP than intended while limiting what the innovator can do with other companies. She walks through how work orders and statements of work can keep scope appropriately narrow, why royalty streams need to account for different regulatory timelines across global markets, and how to structure IP compensation so it qualifies for capital gains treatment rather than ordinary income.

The conversation also covers what a healthy, well-balanced IP partnership actually looks like, why companies may be shifting away from long royalty streams toward milestone payments and flat-rate structures, and the single most common mistake Ast sees innovators make: getting excited and signing a two-year agreement covering all of hip and knee arthroplasty when they were only asked to do one product lab. For any surgeon sitting on an idea, this is the legal foundation you need before your first meeting.

https://www.astcontracts.com/

⏱️ Chapters:
00:00 Meet Emily Ast — contract attorney for surgeon innovators
01:06 Role of a contract attorney in early-stage innovation
01:55 The biggest mindset shift: no off-the-record discussions
02:45 Why you need an NDA before talking to anyone
04:40 Risks of sharing ideas without protection
07:15 The most underestimated clause: product scope definition
09:23 General consulting agreements and hidden IP transfer
11:00 How work orders keep scope appropriately narrow
13:58 Key negotiation points for your first consulting agreement
15:25 IP development agreements: royalties, equity, and structure
17:36 Tax benefits of properly structured IP compensation
18:45 What happens when your IP appears in a product variation
21:40 Regional royalty timing across global markets
24:03 What a healthy IP partnership looks like
27:17 The most common mistake innovators make with industry
28:16 Foundational preparation before meeting with a company
29:52 One piece of advice: protect your napkin idea
31:42 How the surgeon-industry relationship is evolving
34:16 What "from idea to market" means: get your team in place

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #SurgeonInnovator #IntellectualProperty #MedicalDeviceContracts #PhysicianEntrepreneur #NDA #RoyaltyAgreement #OrthopedicInnovation #EmilyAst #IPProtection #ConsultingAgreement #MedTechLaw #FromIdeaToMarket

Send us Fan Mail

A patient had already signed every document — but no one had told her she would lose her stomach. That moment early in her anesthesia training convinced Marie-Isabelle Batthyány that informed consent was fundamentally broken. Years later, she built XRS Medical, a VR platform that replaces paper consent forms with immersive, avatar-delivered patient education and tracks attention in real time using a patented eye-tracking algorithm.

Batthyány walks through exactly what happens from the moment a patient puts on the headset to the moment an attention evaluation report is generated for the surgeon's file. The numbers back it up: 84 percent recall accuracy and 87.5 percent patient satisfaction versus paper forms that almost nobody reads. The platform creates photorealistic digital twins of the operating surgeon, delivers the explanation in the patient's native language, and produces a legal record that the information was delivered and attended to. With over 4,000 patient uses across Austria, Switzerland, Poland, and France, XRS Medical has moved well past proof of concept.

The business story is equally sharp. Batthyány designed the company for acquisition from day one — lean team, phantom shares program, three distinct revenue streams across healthcare providers, pharma, and medical device manufacturers. A surprise pivot into clinical trial consent with Boehringer Ingelheim turned out to be one of the strongest product-market fit moments of the journey. For clinician-founders navigating the European fundraising landscape with a disruptive technology, her playbook on investor fit, due diligence readiness, and the "three threes" rule is essential listening.

https://www.xrs-medical.com/

⏱️ Chapters:
00:00 Meet Marie-Isabelle Batthyány — anesthesiologist turned founder
03:00 The patient who didn't know she would lose her stomach
06:04 From clinical frustration to founding XRS Medical
07:23 Why paper forms and traditional videos fail patients
09:28 How the VR informed consent workflow actually works
14:40 The eye tracking algorithm and US patent
19:40 Early prototypes — from real VR film to digital avatars
26:04 Designing a company for acquisition from day one
28:24 Ideal acquirers: pharma, hospital groups, and three revenue streams
34:41 Advantages of being a physician-led European startup
37:04 How the core team came together
39:41 What medical school never taught about business
46:02 Where XRS Medical is heading: US, Japan, AI avatars
48:08 Advice for future clinician-founders
49:05 What "from idea to market" means: blood, sweat, tears

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #XRSMedical #InformedConsent #VirtualReality #PatientEducation #EyeTracking #MedTechStartup #DigitalHealth #ClinicalTrialConsent #MarieIsabelleBatthyany #ClinicianFounder #MedicalLegalRisk #VRinHealthcare

Send us Fan Mail

Garland Surgical's flagship product, the TriActiv Hip (formerly known as the MaltaHip), replaces the ball-and-socket geometry that has defined hip arthroplasty for 120 years with a cylindrical bearing system inspired by the biomechanics of the ankle joint. Simon Mifsud, CEO of Garland Surgical, explains how this design virtually eliminates dislocation risk and reduced wear by 75 percent in accelerated testing.

Mifsud walks through how the cylindrical design achieves its stability advantage — larger contact area, linear reciprocating motion that avoids cross-shear of the polymer — and why surgeons at AAOS and ACUS told him stability matters far more to them right now than durability. He describes the four patient populations this technology targets, from chronic dislocators and post-spinal-fusion patients to the roughly half of the global population whose daily activities involve squatting and cross-legged sitting. The TriActiv Hip stays in place through all of it while offering range of motion that constrained liners cannot match.

https://www.garlandsurgical.health/

The business story is just as instructive. Garland Surgical is a University of Malta spinout navigating a pre-revenue funding landscape where deep-tech hardware competes against AI and digital health for investor attention. Mifsud shares how a hybrid of equity and non-dilutive grant funding — including a 1.4 million euro Malta Enterprise award — has kept the company moving, and how a successful FDA Q-sub cleared the biggest objection investors had. For innovators building physical devices in a software-obsessed market, this is a roadmap worth studying.

⏱️ Chapters:
00:00 Introducing Simon Mifsud and the TriActiv Hip
00:49 Why ankle biomechanics inspired a new hip design
02:54 Four underserved patient populations
06:19 How cylindrical bearings reduce wear debris
08:18 What "a hip for life" really means
09:41 Proof of concept: cadaver surgery and the garland pose
11:03 Cross-compatibility with existing femoral stems
13:11 Licensing model versus becoming an OEM
15:04 FDA 510(k) pathway and regulatory strategy
16:01 UK launch, ODEP, and training early adopters
17:26 Funding a hardware startup in a software-first market
20:23 How investor feedback shaped the regulatory approach
23:15 What surgeons at AAOS and ACUS actually wanted
26:46 Managing relationships with academic co-inventors
29:26 Where the TriActiv Hip fits in five years
33:27 What "from idea to market" means to Garland Surgical

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #TriActivHip #GarlandSurgical #HipReplacement #TotalHipArthroplasty #THA #HipDislocation #CylindricalBearing #MedicalDeviceStartup #SimonMifsud #HipForLife #510k #OrthopedicInnovation

Send us Fan Mail

Your device just got FDA clearance. So why isn't anyone using it? In this episode of From Idea to Market, Joe Schwab and a panel of surgeons, engineers, and MedTech leaders explore why regulatory approval is only the beginning — and what it actually takes to earn a place in the operating room.

Clearance tells you a device is safe and effective. It doesn't tell you whether a busy surgeon will change their workflow, whether a procurement committee will approve it, or whether a hospital can absorb it into daily practice. This episode unpacks the gap between permission and performance — the space where most MedTech innovations either earn trust or stall out.

Drawing on Everett Rogers' Diffusion of Innovations theory and recent research on early adoption decision-making in surgery, the conversation examines why clinical evidence alone isn't enough. Guests describe how simplicity, immediate benefit, team dynamics, and peer influence determine whether a technology sticks — and why the intention-behavior gap in surgical practice is wider than most companies expect.

The panel also explores how success is redefined after clearance, moving from trial endpoints to real-world outcomes including patient satisfaction, complication rates, workflow efficiency, and health economics. In the PJI space alone, annual hospital costs are projected to reach $1.85 billion by 2030, giving technologies that move the needle enormous clinical and economic significance.

⏱️ Chapters:
00:00 Introduction and series overview
02:34 Meet the panel
05:47 Why clearance is only the beginning
07:42 Diffusion of innovations in surgery
11:07 Investing in data vs inventory after clearance
16:11 The intention-behavior gap in adoption
18:14 Deliberate rollout and early adopter strategy
20:55 Simplicity as the key to surgical adoption
23:18 Market forces behind technology uptake
26:19 Redefining success outside controlled settings
29:24 PJI economics and the case for innovation
33:19 When innovation becomes the standard of care
36:52 Three lessons from life after clearance

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #MedTechAdoption #RegulatoryStrategy #FDAClearance #DiffusionOfInnovations #SurgicalInnovation #TotalHipArthroplasty #PJI #PeriprostheticJointInfection #RealWorldEvidence #OrthopedicSurgery #FromIdeaToMarket #MedicalDeviceAdoption

Send us Fan Mail

Charlie DeCook has exited seven medical device companies while performing 1,500 joint replacements a year — all packed into three clinical days per week. In this extended interview, he breaks down exactly how he evaluates new technologies and why he now filters every opportunity through an AI and robotics lens.

DeCook traces his entrepreneurial arc from his first venture in surgical impaction — a product that eventually sold to Johnson & Johnson and became Kincise — through to his current focus on software-driven solutions. He explains why the "jobs to be done" framework from Clayton Christensen's Innovator's Dilemma is the foundation of every product he touches, and why surgeons who skip the financial model are setting themselves up for years of pain. Along the way, he offers a candid look at how large device companies operate, including the "slow no" that strings inventor-surgeons along for months without a real commitment.

The conversation also covers the AHF Shark Tank program and what separates pitches that land from those that get eaten alive. Whether you are a surgeon sitting in the OR frustrated with an inefficiency, or a founder trying to get traction with the big three, DeCook's hard-won playbook is worth hearing in full.

⏱️ Chapters:
00:00 Meet Charlie DeCook — surgeon, serial entrepreneur
02:11 First venture: surgical impaction to Johnson & Johnson
03:29 Filtering ideas with easier, faster, better
05:22 Patient outcomes vs commercial reality in med-tech
07:43 Why cost concerns work themselves out over time
09:02 Strategic shift from hardware to AI and robotics
10:41 Finding innovation through jobs to be done in the OR
12:43 Lessons from ventures that required major pivots
14:49 Protecting IP from large device companies
17:27 Why public companies can't think past the quarter
19:02 Evaluating products beyond your own efficiency lens
21:40 What makes a winning AHF Shark Tank pitch
24:29 Common mistakes surgeon-entrepreneurs make pitching
27:17 Innovation areas the Shark Tank needs more of
29:25 Top advice for surgeons with a great OR idea
31:45 What innovation in orthopedics really means

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #SurgeonEntrepreneur #MedicalDeviceStartup #OrthopedicInnovation #TotalJointArthroplasty #SurgicalImpaction #AIinOrthopedics #RoboticSurgery #JobsToBeDone #AHFSharkTank #CharlieDeCook #MedTechEntrepreneur #THA